companies innovating obesity treatment glp-1 drugs 2025 Morningstar

A new review by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, describes a new generation of treatment with GLP-1 receptor agonists for persons with obesity with or without diabetes or

How GLP-1 Receptor Agonists Evolved from Diabetes Treatments to Weight Loss Treatments

Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight | Hypertension Research

GLP-1 medications like Ozempic, Wegovy and Mounjaro are changing diabetes and weight management, but they aren't recommended during pregnancy or while nursing. The current recommendation is to stop before conception and discuss

Although many of the names are used interchangeably, not all GLP-1 agonist medications are the same. For example, semaglutide is the active ingredient in Ozempic and Wegovy, and while the active ingredient